^
    Back
    Association details:
    Biomarker:KRAS mutation + PD-L1 expression
    Cancer:Biliary Tract Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2023
    Title:

    4403 / 16 - The Efficacy of Immune Checkpoint Inhibitors in Advanced Biliary Tract Cancer with KRAS Mutation

    Published date:
    03/15/2023
    Excerpt:
    In subgroup analysis, patients with both KRAS mutation and PD-L1 positivity had longer PFS as compared to patients with KRAS mutation and PD-L1 negativity (6.5 vs 2.6 months, p=0.047).